Alps Advisors Inc. grew its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 181,604 shares of the biopharmaceutical company’s stock after purchasing an additional 20,726 shares during the period. Alps Advisors Inc. owned approximately 0.11% of Horizon Pharma worth $2,651,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in HZNP. Paulson & CO. Inc. bought a new stake in shares of Horizon Pharma in the 2nd quarter valued at approximately $58,584,000. Ameriprise Financial Inc. grew its stake in shares of Horizon Pharma by 419.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,127,694 shares of the biopharmaceutical company’s stock valued at $26,979,000 after purchasing an additional 1,717,841 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Horizon Pharma by 18.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after purchasing an additional 1,167,722 shares during the period. State Street Corp grew its stake in shares of Horizon Pharma by 12.0% in the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock valued at $58,241,000 after purchasing an additional 524,187 shares during the period. Finally, Principal Financial Group Inc. grew its stake in shares of Horizon Pharma by 1,865.4% in the 3rd quarter. Principal Financial Group Inc. now owns 399,132 shares of the biopharmaceutical company’s stock valued at $5,060,000 after purchasing an additional 378,824 shares during the period. Institutional investors own 85.70% of the company’s stock.
Horizon Pharma PLC (HZNP) traded down $0.02 during trading hours on Friday, reaching $14.09. The company’s stock had a trading volume of 1,097,600 shares, compared to its average volume of 1,684,391. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $17.69. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The firm has a market cap of $2,312.43, a P/E ratio of -4.62, a price-to-earnings-growth ratio of 0.66 and a beta of 1.35.
A number of equities research analysts recently commented on the company. Cantor Fitzgerald set a $17.00 price target on Horizon Pharma and gave the stock a “buy” rating in a research report on Monday, January 8th. Stifel Nicolaus restated a “buy” rating and set a $20.00 price target on shares of Horizon Pharma in a research report on Sunday, October 22nd. UBS Group set a $20.00 price target on Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, November 30th. ValuEngine lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub upgraded Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $19.25.
COPYRIGHT VIOLATION WARNING: “Alps Advisors Inc. Boosts Holdings in Horizon Pharma PLC (HZNP)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/16/horizon-pharma-plc-hznp-shares-bought-by-alps-advisors-inc.html.
Horizon Pharma Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.